MX388231B - Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. - Google Patents

Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Info

Publication number
MX388231B
MX388231B MX2017005126A MX2017005126A MX388231B MX 388231 B MX388231 B MX 388231B MX 2017005126 A MX2017005126 A MX 2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A MX 388231 B MX388231 B MX 388231B
Authority
MX
Mexico
Prior art keywords
prognosis
diagnosis
kidney
compositions
methods
Prior art date
Application number
MX2017005126A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005126A (es
Inventor
Joseph Anderberg
Jeff Gray
James Patrick Kampf
Thomas Kwan
Paul Mcpherson
Kevin Nakamura
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2017005126A publication Critical patent/MX2017005126A/es
Publication of MX388231B publication Critical patent/MX388231B/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/521Chemokines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2017005126A 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. MX388231B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066310P 2014-10-20 2014-10-20
US201462066313P 2014-10-20 2014-10-20
US201462066316P 2014-10-20 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2017005126A MX2017005126A (es) 2017-09-15
MX388231B true MX388231B (es) 2025-03-19

Family

ID=55761743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005126A MX388231B (es) 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Country Status (13)

Country Link
US (2) US11333671B2 (https=)
EP (2) EP3210018B1 (https=)
JP (4) JP6792553B2 (https=)
KR (1) KR102431003B1 (https=)
CN (2) CN110702921B (https=)
AU (2) AU2015336069B2 (https=)
BR (1) BR112017008218A2 (https=)
CA (1) CA2965153C (https=)
EA (1) EA201790696A1 (https=)
ES (1) ES2907551T3 (https=)
MX (1) MX388231B (https=)
PT (1) PT3210018T (https=)
WO (1) WO2016064877A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2965153C (en) 2014-10-20 2023-10-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP4063853A1 (en) * 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US11891439B2 (en) 2017-12-28 2024-02-06 Astute Medical, Inc. Antibodies and assays for CCL14
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
CN119454032A (zh) * 2018-04-02 2025-02-18 波特雷罗医疗公司 用于排出和分析体液并评估健康的系统、设备和方法
CN114207436A (zh) * 2019-05-24 2022-03-18 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量而评估和治疗肾损伤的方法
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
EP4247395A4 (en) * 2020-11-18 2024-09-18 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure
CA3253529A1 (en) * 2022-03-03 2023-09-07 Astute Medical, Inc. METHODS AND COMPOSITIONS FOR EVALUATING AND TREATING PERSISTENT ACUTE RENAL INJURY BASED ON A C-C MOTIFYING CHEMOKIN LIGAND MEASUREMENT 14

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU2003223172A1 (en) 2002-02-12 2003-09-04 Quark Biotech, Inc. Use of the axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
EP1915614A4 (en) 2005-07-21 2009-03-25 Univ Johns Hopkins METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
CA2740923A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462437A4 (en) * 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
CA2774223A1 (en) 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010315008B2 (en) 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600160A (en) * 2009-11-07 2014-05-30 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) * 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) * 2010-06-23 2015-05-22 Astute Medical Inc
NZ606124A (en) * 2010-06-23 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
PT2748605T (pt) 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US10935548B2 (en) * 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP2962109A4 (en) 2013-02-26 2016-12-07 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CA2965153C (en) 2014-10-20 2023-10-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
JP6792553B2 (ja) 2020-11-25
JP2023052587A (ja) 2023-04-11
US20220236286A1 (en) 2022-07-28
JP2021039112A (ja) 2021-03-11
BR112017008218A2 (pt) 2018-01-09
JP2022046669A (ja) 2022-03-23
WO2016064877A2 (en) 2016-04-28
ES2907551T3 (es) 2022-04-25
AU2015336069A1 (en) 2017-05-25
CA2965153C (en) 2023-10-24
CN107003301B (zh) 2019-11-01
CN110702921A (zh) 2020-01-17
AU2015336069B2 (en) 2021-11-25
EA201790696A1 (ru) 2017-10-31
JP7217796B2 (ja) 2023-02-03
CN110702921B (zh) 2024-02-06
CA2965153A1 (en) 2016-04-28
AU2022201130B2 (en) 2024-06-27
KR102431003B1 (ko) 2022-08-09
KR20170084102A (ko) 2017-07-19
EP3968022A1 (en) 2022-03-16
EP3210018B1 (en) 2021-07-28
AU2022201130A1 (en) 2022-03-17
JP2017533427A (ja) 2017-11-09
EP3210018A4 (en) 2018-06-20
US11333671B2 (en) 2022-05-17
JP7002623B2 (ja) 2022-02-10
EP3210018A2 (en) 2017-08-30
US12099067B2 (en) 2024-09-24
CN107003301A (zh) 2017-08-01
US20180209990A1 (en) 2018-07-26
MX2017005126A (es) 2017-09-15
PT3210018T (pt) 2021-10-04
WO2016064877A3 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
MX388231B (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
MX386919B (es) Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática.
NZ738100A (en) Igfbp3 and uses thereof
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
BR112018067292A2 (pt) métodos e composições para a detecção e o diagnóstico de doença renal e doença periodontal
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
WO2016089732A3 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
MX2016009450A (es) Ensayo novedoso para detectar periostina humana.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX362049B (es) Métodos para tratar, diagnosticar y pronosticar una malignidad hematológica.
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same
BR112016003058A2 (pt) composições e métodos para análise multiplex de ácidos nucleicos nras e braf
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
WO2015091963A3 (en) Determination of platelet-mirnas in acute myocardial infarction